Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target

Autor: Pcw Hogendoorn, Jaap Verweij, O.S. Nielsen, Ian Judson, Sjoerd Rodenhuis, John Radford, Jean-Yves Blay, E. Donato Di Paola, W.T.A. van der Graaf, M. Brown, A. Le Cesne, A. van Oosterom

Publikováno v: European Journal of Cancer. 39:2006-2011

The aim of this study was to assess the antitumour response and time to progression (TTP) of patients treated with imatinib mesylate (Glivec®, Gleevec™, formerly STI-571) who had advanced and/or metastatic gastrointestinal stroma tumours (GIST) or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9fcb223c6a57d93dfd887318b7cad735
https://doi.org/10.1016/s0959-8049(02)00836-5

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma

Autor: John Radford, Jean-Yves Blay, Claus Kamby, A. van Oosterom, Q.G.C.M. van Hoesel, E. Donato Di Paola, Cédric Hermans, S Nielsen, A. Le Cesne, Jaap Verweij, Maggie A Harris, Mark Clemons, J Whittaker, Ian Judson

Publikováno v: European Journal of Cancer. 37:870-877

CAELYX/DOXIL, pegylated liposomal doxorubicin, has shown antitumour activity and reduced toxicity compared with standard doxorubicin in other tumour types. In this prospective randomised trial, 94 eligible patients with advanced soft-tissue sarcoma (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::abbe367184b5e4273243712494f08eb6
https://doi.org/10.1016/s0959-8049(01)00050-8

Clinical Trials methodology and elderly

Autor: Pietro Gareri, S. De Fazio, Emilio Russo, E. Donato Di Paola, G. De Sarro

Publikováno v: BMC Geriatrics, Vol 10, Iss Suppl 1, p L62 (2010)
BMC Geriatrics

Due to the ageing of the population and the sharp increase in life expectancy, cancer diagnosed in the elderly population is rising and it has become an increasingly common problem in the Western world. According to the National Cancer Institute (NCI

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59ad0c83ae7780e81fd94238dbc99930
https://doi.org/10.1186/1471-2318-10-s1-l62

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

Autor: Sylvie Bonvalot, Paul Lorigan, M. van Glabbeke, Isabelle Ray-Coquard, Ole S. Nielsen, A. Le Cesne, John Radford, Jaap Verweij, J.-Y. Blay, Sjoerd Rodenhuis, A. van Oosterom, F. Collin, E. Donato Di Paola, Ian Judson, J. Jimeno

Publikováno v: Le Cesne, A, Blay, J Y, Judson, I, Van Oosterom, A, Verweij, J, Radford, J, Lorigan, P, Rodenhuis, S, Ray-Coquard, I, Bonvalot, S, Jimeno, J, Di Paola, E, Van Glabbeke, M & Nielsen, O S 2005, ' Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial ', Journal of Clinical Oncology, vol. 23, no. 3, pp. 576-84 . https://doi.org/10.1200/JCO.2005.01.180
Journal of clinical oncology, 23(3), 576-584. American Society of Clinical Oncology

Purpose This nonrandomized multicenter phase II study was performed to evaluate the activity and safety of Ecteinascidin (ET-743) administered at a dose of 1.5 mg/m2 as a 24-hour continuous infusion every 3 weeks in patients with pretreated advanced

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ff4b4c42d170cbe7de758a656039157
https://pure.au.dk/portal/da/publications/phase-ii-study-of-et743-in-advanced-soft-tissue-sarcomas-a-european-organisation-for-the-research-and-treatment-of-cancer-eortc-soft-tissue-and-bone-sarcoma-group-trial(c765e15e-f833-4c43-90dd-4acf5defe777).html

The EORTC soft tissue and bone sarcoma group. European Organisation for Research and Treatment of Cancer

Autor: E, Donato Di Paola, O S, Nielsen

Publikováno v: European journal of cancer (Oxford, England : 1990). 38

The EORTC Soft Tissue Sarcoma Group was founded 25 years ago and has since developed into one of the leading cooperative groups in the research of sarcomas and has members from 40 institutions from 13 countries. The activities of the group have prima

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3ebc6f1392fc9ca9f326b1ee715f75e4
https://pubmed.ncbi.nlm.nih.gov/11858980